Nouscom develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The Company offers Endovax antigenless vaccine that encodes immunomodulators, breaks tolerance, and primes/rescues cancer-specific immune response; and Exovax personalized vaccine that encodes neoantigens and boosts cancer-specific responses for sustained immunity. Its technology is based on viral vectors and oncolytic viruses.
|Employees (est.) (Sept 2020)||24||(+5%)|
Nouscom total Funding
Nouscom latest funding size
Time since last funding
|3 years ago|
|Versant Ventures, 5AM Ventures, Abingworth, LSP BioVentures, LSP|
When was Nouscom founded?
Nouscom was founded in 2015.
Who are Nouscom key executives?
Nouscom's key executives are Riccardo Cortese, Marina Udier and Stefano Colloca.
How many employees does Nouscom have?
Nouscom has 24 employees.
Who are Nouscom competitors?
Competitors of Nouscom include Orchard Therapeutics, Stealth BioTherapeutics and Affinia Therapeutics.
Where is Nouscom headquarters?
Nouscom headquarters is located at 18 Bäumleingasse, Basel.
Where are Nouscom offices?
Nouscom has offices in Basel and Roma.
How many offices does Nouscom have?
Nouscom has 2 offices.
Receive alerts for 300+ data fields across thousands of companies